Final3‐year clinical outcomes following transcatheter aortic valve implantation with a supra‐annular self‐expanding repositionable valve in a real‐world setting : Results from the multicenter FORWARD study
Abstract Objectives The Evolut R FORWARD study confirmed safety and effectivenesss of the Evolut R THV in routine clinical practice out to 1 year. Herein, we report the final 3‐year clinical follow up of the FORWARD study. Background Transcatheter aortic valve replacement (TAVR) is a proven alternative to surgery in elderly patients with symptomatic severe aortic stenosis. Long‐term clinical outcome data with the Evolut R platform are scarce. Methods FORWARD is a prospective multicenter observational study that evaluated the Evolut R system in routine clinical practice at 53 centres. Eligible patients had symptomatic native aortic valve stenosis or failed surgical aortic bioprosthesis and elevated operative risk per Heart‐Team assessment. TAVR was attempted in 1039 patients. Results Mean age was 81.8 ± 6.2 years, 64.9% were women, STS score was 5.5 ± 4.5% and 34.2% were frail. Rates of all‐cause mortality and disabling stroke were 24.8% and 4.8% at 3 years. Early need for a new pacemaker implantation after TAVR (all‐cause mortality: with new PPI; 21.0% vs. without; 22.8%, p = 0.55) and the presence of > trace paravalvular regurgitation (all‐cause mortality: no or trace; 22.0% vs. ≥ mild; 25.5%, p = 0.29) did not affect survival. Between 1 and 3 years incidence rates of valve related intervention, endocarditis and clinically relevant valve thrombosis were low. Conclusions The Evolut R valve maintained a favorable safety profile through 3 years in routine clinical practice. Rates of transcatheter heart valve‐related adverse events were low..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
Catheterization and Cardiovascular Interventions - 99(2022), 1, Seite 171-178 |
| Beteiligte Personen: |
Van Mieghem, Nicolas M. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 Wiley Periodicals LLC. |
|---|
| Umfang: |
8 |
|---|
| doi: |
10.1002/ccd.29889 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY003183424 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY003183424 | ||
| 003 | DE-627 | ||
| 005 | 20230307124311.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230213s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/ccd.29889 |2 doi | |
| 028 | 5 | 2 | |a CCD_CCD29889.xml |
| 035 | |a (DE-627)WLY003183424 | ||
| 035 | |a (WILEY)CCD29889 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.51 |2 bkl | ||
| 084 | |a 44.85 |2 bkl | ||
| 100 | 1 | |a Van Mieghem, Nicolas M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Final3‐year clinical outcomes following transcatheter aortic valve implantation with a supra‐annular self‐expanding repositionable valve in a real‐world setting |b Results from the multicenter FORWARD study |
| 264 | 1 | |c 2022 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 Wiley Periodicals LLC. | ||
| 520 | |a Abstract Objectives The Evolut R FORWARD study confirmed safety and effectivenesss of the Evolut R THV in routine clinical practice out to 1 year. Herein, we report the final 3‐year clinical follow up of the FORWARD study. Background Transcatheter aortic valve replacement (TAVR) is a proven alternative to surgery in elderly patients with symptomatic severe aortic stenosis. Long‐term clinical outcome data with the Evolut R platform are scarce. Methods FORWARD is a prospective multicenter observational study that evaluated the Evolut R system in routine clinical practice at 53 centres. Eligible patients had symptomatic native aortic valve stenosis or failed surgical aortic bioprosthesis and elevated operative risk per Heart‐Team assessment. TAVR was attempted in 1039 patients. Results Mean age was 81.8 ± 6.2 years, 64.9% were women, STS score was 5.5 ± 4.5% and 34.2% were frail. Rates of all‐cause mortality and disabling stroke were 24.8% and 4.8% at 3 years. Early need for a new pacemaker implantation after TAVR (all‐cause mortality: with new PPI; 21.0% vs. without; 22.8%, p = 0.55) and the presence of > trace paravalvular regurgitation (all‐cause mortality: no or trace; 22.0% vs. ≥ mild; 25.5%, p = 0.29) did not affect survival. Between 1 and 3 years incidence rates of valve related intervention, endocarditis and clinically relevant valve thrombosis were low. Conclusions The Evolut R valve maintained a favorable safety profile through 3 years in routine clinical practice. Rates of transcatheter heart valve‐related adverse events were low. | ||
| 700 | 1 | |a Windecker, Stephan |4 aut | |
| 700 | 1 | |a Manoharan, Ganesh |4 aut | |
| 700 | 1 | |a Bosmans, Johan |4 aut | |
| 700 | 1 | |a Bleiziffer, Sabine |4 aut | |
| 700 | 1 | |a Modine, Thomas |4 aut | |
| 700 | 1 | |a Linke, Axel |4 aut | |
| 700 | 1 | |a Scholtz, Werner |4 aut | |
| 700 | 1 | |a Tchétché, Didier |4 aut | |
| 700 | 1 | |a Finkelstein, Ariel |4 aut | |
| 700 | 1 | |a Ito, Saki |4 aut | |
| 700 | 1 | |a Eisenberg, Ruth |4 aut | |
| 700 | 1 | |a Grube, Eberhard |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Catheterization and Cardiovascular Interventions |g 99(2022), 1, Seite 171-178 |w (DE-627)WLY003164713 |x 1522726X |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2022 |g number:1 |g pages:171-178 |g extent:8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.51 |q ASE |
| 936 | b | k | |a 44.85 |q ASE |
| 951 | |a AR | ||
| 952 | |d 99 |j 2022 |e 1 |h 171-178 |g 8 | ||